46 results found
    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine

    RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development

    Renaud Mevel et al.
    The transcription factor RUNX1 marks a distinct lineage of luminal castration-resistant prostate cells established early during development and enriched in the periurethral region of adult mouse prostate.
    1. Developmental Biology
    2. Genetics and Genomics

    Castration delays epigenetic aging and feminizes DNA methylation at androgen-regulated loci

    Victoria J Sugrue et al.
    Epigenetic clocks are an accurate measure of biological aging and 'tick' slower in male sheep that are castrated.
    1. Cancer Biology
    2. Stem Cells and Regenerative Medicine

    Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation

    Chee Wai Chua et al.
    Analyses of genetically engineered mouse models reveal the androgen receptor-independent properties of a luminal stem/progenitor cell in the prostate epithelium, and its ability to serve as a cell of origin for castration-resistant prostate cancer.
    1. Cancer Biology

    A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth

    Joanna L Gillis et al.
    A positive feedback loop between the androgen receptor and a key pentose phosphate pathway enzyme, 6PGD, in prostate cancer promotes tumour cell proliferation, survival and intracellular redox control.
    1. Cancer Biology

    Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis

    Zeyad D Nassar et al.
    DECR1, a rate-limiting enzyme for polyunsaturated fatty acid (PUFA) β-oxidation, is an androgen-repressed gene in prostate cancer cells that limits oxidative stress to promote cancer cell survival.
    1. Cancer Biology

    Overcoming mutation-based resistance to antiandrogens with rational drug design

    Minna D Balbas et al.
    Mutagenesis studies identified an androgen receptor mutation that converts enzalutamide-a drug recently approved for the treatment of advanced prostate cancer-into an androgen receptor agonist, and modeling studies informed the design of novel drugs that are effective against the mutant receptor.
    1. Cancer Biology

    Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer

    Neel Shah et al.
    Epigenetic regulation of the glucocorticoid receptor in castration-resistant prostate cancer can be targeted via the use of BET bromodomain inhibitors.
    1. Genetics and Genomics

    Ovariectomy uncouples lifespan from metabolic health and reveals a sex-hormone-dependent role of hepatic mTORC2 in aging

    Sebastian I Arriola Apelo et al.
    Metabolic health and longevity can be separated by ovariectomy, which also protects female mice lacking hepatic mTORC2 from midlife mortality.
    1. Cancer Biology

    TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

    Sander AL Palit et al.
    A mechanistic link between TLE3 loss and glucocorticoid receptor-mediated androgen receptor inhibitor resistance supports the rationale to target GR during anti-hormonal treatment in castrate-resistant prostate cancer.
    1. Biochemistry and Chemical Biology
    2. Cancer Biology

    Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer

    Jianneng Li et al.
    Prostate cancer resistance to androgen receptor antagonist therapy occurs by way of tumors impeding local glucocorticoid metabolism and inactivation and thereby permitting sustained glucocorticoids to stimulate up-regulated glucocorticoid receptor.

Refine your results by:

Type
Research categories